321 related articles for article (PubMed ID: 18971369)
1. Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients.
Nasr SH; Valeri AM; Appel GB; Sherwinter J; Stokes MB; Said SM; Markowitz GS; D'Agati VD
Clin J Am Soc Nephrol; 2009 Jan; 4(1):22-32. PubMed ID: 18971369
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors and therapy assessment of IgA nephropathy: report from a single unit in iran.
Soleymanian T; Najafi I; Salimi BH; Broomand B
Ren Fail; 2011; 33(6):572-7. PubMed ID: 21663387
[TBL] [Abstract][Full Text] [Related]
3. C1q nephropathy: a variant of focal segmental glomerulosclerosis.
Markowitz GS; Schwimmer JA; Stokes MB; Nasr S; Seigle RL; Valeri AM; D'Agati VD
Kidney Int; 2003 Oct; 64(4):1232-40. PubMed ID: 12969141
[TBL] [Abstract][Full Text] [Related]
4. Eculizumab in Pediatric Dense Deposit Disease.
Oosterveld MJ; Garrelfs MR; Hoppe B; Florquin S; Roelofs JJ; van den Heuvel LP; Amann K; Davin JC; Bouts AH; Schriemer PJ; Groothoff JW
Clin J Am Soc Nephrol; 2015 Oct; 10(10):1773-82. PubMed ID: 26316621
[TBL] [Abstract][Full Text] [Related]
5. C3 glomerulopathy: clinicopathologic features and predictors of outcome.
Medjeral-Thomas NR; O'Shaughnessy MM; O'Regan JA; Traynor C; Flanagan M; Wong L; Teoh CW; Awan A; Waldron M; Cairns T; O'Kelly P; Dorman AM; Pickering MC; Conlon PJ; Cook HT
Clin J Am Soc Nephrol; 2014 Jan; 9(1):46-53. PubMed ID: 24178974
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneous histologic and clinical evolution in 3 cases of dense deposit disease with long-term follow-up.
Figuères ML; Frémeaux-Bacchi V; Rabant M; Galmiche L; Marinozzi MC; Grünfeld JP; Noël LH; Servais A
Hum Pathol; 2014 Nov; 45(11):2326-33. PubMed ID: 25260719
[TBL] [Abstract][Full Text] [Related]
7. Dense intramembranous deposit disease: a clinical comparison of histological subtypes.
Kashtan CE; Burke B; Burch G; Gustav Fisker S; Kim Y
Clin Nephrol; 1990 Jan; 33(1):1-6. PubMed ID: 2302866
[TBL] [Abstract][Full Text] [Related]
8. Clinico-pathologic spectrum of C3 glomerulopathy-an Indian experience.
Viswanathan GK; Nada R; Kumar A; Ramachandran R; Rayat CS; Jha V; Sakhuja V; Joshi K
Diagn Pathol; 2015 Mar; 10():6. PubMed ID: 25889427
[TBL] [Abstract][Full Text] [Related]
9. Combined renin angiotensin blockade in childhood steroid-resistant nephrotic syndrome.
Supavekin S; Surapaitoolkorn W; Tancharoen W; Pattaragarn A; Sumboonnanonda A
Pediatr Int; 2012 Dec; 54(6):793-7. PubMed ID: 22621380
[TBL] [Abstract][Full Text] [Related]
10. [Primary nephrotic syndrome. Follow-up of 202 pediatric patients].
Caletti MG; Gallo G; Zumino D; Díaz MA; Vitacco M
Bol Med Hosp Infant Mex; 1981; 38(3):457-72. PubMed ID: 7271977
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors in children with membranoproliferative glomerulonephritis type I.
García-de la Puente S; Orozco-Loza IL; Zaltzman-Girshevich S; de Leon Bojorge B
Pediatr Nephrol; 2008 Jun; 23(6):929-35. PubMed ID: 18297315
[TBL] [Abstract][Full Text] [Related]
12. Collapsing glomerulopathy in 19 patients with systemic lupus erythematosus or lupus-like disease.
Salvatore SP; Barisoni LM; Herzenberg AM; Chander PN; Nickeleit V; Seshan SV
Clin J Am Soc Nephrol; 2012 Jun; 7(6):914-25. PubMed ID: 22461531
[TBL] [Abstract][Full Text] [Related]
13. Pattern of steroid resistant nephrotic syndrome in children living in the kingdom of Saudi Arabia: a single center study.
Kari JA; Halawani M; Mokhtar G; Jalalah SM; Anshasi W
Saudi J Kidney Dis Transpl; 2009 Sep; 20(5):854-7. PubMed ID: 19736491
[TBL] [Abstract][Full Text] [Related]
14. Immunosuppressive treatment of the nephrotic syndrome due to mesangial lesions.
Faedda R; Pirisi M; Satta A; Tanda F; Bartoli E
Clin Nephrol; 1996 Oct; 46(4):237-44. PubMed ID: 8905208
[TBL] [Abstract][Full Text] [Related]
15. Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on renin angiotensin aldosterone system blockade: a prospective 50-month Mayo-Health-System clinic analysis.
Onuigbo MA; Onuigbo NT
QJM; 2008 Jul; 101(7):519-27. PubMed ID: 18375475
[TBL] [Abstract][Full Text] [Related]
16. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin receptor blocker reduces proteinuria independently of blood pressure in children already treated with Angiotensin-converting enzyme inhibitors.
Seeman T; Pohl M; Misselwitz J; John U
Kidney Blood Press Res; 2009; 32(6):440-4. PubMed ID: 20016211
[TBL] [Abstract][Full Text] [Related]
18. Idiopathic membranous nephropathy and nephrotic syndrome: outcome in the era of evidence-based therapy.
McQuarrie EP; Stirling CM; Geddes CC
Nephrol Dial Transplant; 2012 Jan; 27(1):235-42. PubMed ID: 21558430
[TBL] [Abstract][Full Text] [Related]
19. [Characteristics of pediatric C3 glomerulopathy with decreased factor H in 3 cases].
He RJ; Xiao HJ; Wang SX; Guan N; Yao Y; Ding J
Zhonghua Er Ke Za Zhi; 2012 Dec; 50(12):939-43. PubMed ID: 23324154
[TBL] [Abstract][Full Text] [Related]
20. Low-dose dual blockade of the renin-angiotensin system improves tubular status in non-diabetic proteinuric patients.
Renke M; Tylicki L; Rutkowski P; Wojnarowski K; Lysiak-Szydlowska W; Rutkowski B
Scand J Urol Nephrol; 2005; 39(6):511-7. PubMed ID: 16303729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
